BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pastwińska J, Karaś K, Karwaciak I, Ratajewski M. Targeting EGFR in melanoma - The sea of possibilities to overcome drug resistance. Biochim Biophys Acta Rev Cancer 2022;1877:188754. [PMID: 35772580 DOI: 10.1016/j.bbcan.2022.188754] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Noguchi S, Yasumura M. The potential therapeutic efficiency of pan-ERBB inhibitors for canine glioma.. [DOI: 10.21203/rs.3.rs-2452372/v1] [Reference Citation Analysis]
2 Ji F, Qiu X. Non-Apoptotic Programmed Cell Death in Thyroid Diseases. Pharmaceuticals (Basel) 2022;15. [PMID: 36559016 DOI: 10.3390/ph15121565] [Reference Citation Analysis]
3 Mahdavi Gorabi A, Sadat Ravari M, Sanaei M, Davaran S, Kesharwani P, Sahebkar A. Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles. International Immunopharmacology 2022;113:109300. [DOI: 10.1016/j.intimp.2022.109300] [Reference Citation Analysis]
4 Slastnikova TA, Rosenkranz AA, Ulasov AV, Khramtsov YV, Lupanova TN, Georgiev GP, Sobolev AS. Mouse Syngeneic Melanoma Model with Human Epidermal Growth Factor Receptor Expression. Pharmaceutics 2022;14. [PMID: 36432639 DOI: 10.3390/pharmaceutics14112448] [Reference Citation Analysis]